By Deepak GuptaThe world’s largest pharmaceutical company, Pfizer, is facing a shortage of drugs and its brand is losing traction.
The global pharmaceutical market is worth about $1.2 trillion and Pfizer is one of the biggest producers, with around half the global market.
India has become the largest market for the drugmaker.
It has been the target of attacks on its brand in recent years, and some analysts say that it has also been a target of threats against its brand.
But the world’s biggest pharmaceutical company has been hit by the sharp rise of generics, which make medicines cheaper.
The rise of generic drugs, and the availability of cheaper generics in India, have led to a slowdown in the growth of the pharmaceutical industry in the country.
According to industry experts, the generic drug makers have been selling drugs at prices lower than the industry’s average, and this has led to higher demand.
The price of the drug used by the Indian Medical Council (IMC) has risen from around $2.50 to about $4 a tablet, and its generic competitors have also been able to raise prices by about 50 per cent.
According the Pharma India Federation (PIF), the Indian pharma market is set to grow to about 7.7 billion rupees ($1.7 trillion) by 2020, and a staggering 8.3 billion rupee ($2.4 trillion) in 2021, up from 7.2 billion ruple.
The demand for generic drugs has also slowed down the growth in the industry.
The number of generic medicines sold to the market grew from 4.3 million in the first half of 2017 to 6.2 million in May 2018, according to the IMC, and in May 2019, the number of generic medicines sold increased to about 6.7 million from 4 million.